SCHEMBL14909356

SCHEMBL14909356

COc1cc(N)cc(-c2ccccc2)n1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.72
NPC1 O15118 2/20 0.72
RAB9A P51151 2/20 0.72
MEN1 O00255 6/20 0.56
KMT2A Q03164 6/20 0.56
MAPT P10636 3/20 0.56
TSHR P16473 2/20 0.56
ATM Q13315 2/20 0.56
ADORA2A P29274 2/20 0.52
ADORA1 P30542 2/20 0.52
HPGD P15428 4/20 0.50
MAPK1 P28482 2/20 0.49
LMNA P02545 2/20 0.49
SQOR Q9Y6N5 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
KDM4E B2RXH2 4/20 0.47
ASIC3 Q9UHC3 2/20 0.47
HSD17B10 Q99714 2/20 0.45
USP2 O75604 1/20 0.45
HTT P42858 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17372960 0.83 NPC1 (0.64) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL4257668 0.82 ADORA2A (0.67) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL30380157 0.82 CYP19A1 (0.51) ALDH1A1NPC1RAB9AMEN1SQOR
SCHEMBL20765132 0.82 CYP19A1 (0.51) ALDH1A1NPC1RAB9AMEN1SQOR
SCHEMBL14909965 0.80 NPC1 (0.52) ALDH1A1NPC1RAB9AMAPK1SQOR
SCHEMBL27176093 0.80 ALDH1A1 (0.60) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL4716253 0.79 ALDH1A1 (0.50) ALDH1A1NPC1RAB9ATSHRHPGD
SCHEMBL14927819 0.78 NPC1 (0.57) ALDH1A1NPC1RAB9AMAPK1ASIC3
SCHEMBL19417187 0.78 MEN1 (0.64) ALDH1A1NPC1RAB9AMEN1KMT2A
SCHEMBL13019371 0.78 ALDH1A1 (0.67) ALDH1A1NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2589592-B1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM CORP (JP) 2018-08-22 EP disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8895585-B2 Nicotinamide derivative or salt thereof FUJIFILM CORPORATION (JP) 2014-11-25 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8809371-B2 2014-08-19 US disclosed
US-8772320-B2 2014-07-08 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2013-05-09 US disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 EP disclosed
EP-2589592-A1 NOVEL NICOTINAMIDE DERIVATIVES OR SALTS THEREOF FUJIFILM Corporation (JP) 2013-05-08 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116430-A1 NOVEL NICOTINAMIDE DERIVATIVE OR SALT THEREOF SYK, CD38, BTK ALDH1A1 1638/4885NPC1 1367/4885RAB9A 2445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.